Valeant Canada acquires Valeo Pharma's portfolio

The pharmaceutical company consolidates its leadership position in dermatology in Canada

LAVAL, QC, Aug. 25, 2014 /CNW Telbec/ - Valeant Canada today announced it has completed the acquisition of Valeo Pharma's dermatology product portfolio and several specialty products.

Valeo Pharma is a Montreal-based pharmaceutical company offering high quality dermatology and specialty products.

Founded in 2003, Valeo Pharma's portfolio includes brands such as Aristocort C and Valisone G. These treatments add to Valeant Canada's existing line of dermatitis solutions, joining Elidel, Dermatop, Topicort, UltraVate and CeraVe. The acquisition also includes Veralac for nail dystrophy, which complements Valeant Canada's recently launched topical solution, Jublia, for onychomycosis. Valeo Pharma's portfolio also comprises the specialty products Vancomycin, an injectable antibiotic for severe staphylococcal infections, and Cophylac, a well-known antitussive.

The acquisition of this complementary portfolio of products supports Valeant Canada's desire to build on its current product offering and to meet physician and patient needs. 

"As a Canadian company, we are proud to solidify our position as a leader and to reaffirm our long-term commitment to the field of Dermatology," said Jacques Dessureault, President and General Manager of Valeant Canada.

Valeant Canada has a proven track record of successfully integrating a number of major acquisitions into its portfolio and has established a significant presence in the dermatology market over the last years. The addition of the Valeo Pharma portfolio creates a very compelling platform for future growth in the medical dermatology segment. 

Valeant Canada's recent acquisition and integration initiatives include the acquisition of Dermik, Medicis, Obagi, Bausch & Lomb, Solta Medical and Pro-Derma.

About Valeant Canada

Valeant Canada is a subsidiary of Valeant Pharmaceuticals International, Inc., a multinational specialty pharmaceutical company that develops, manufactures, and markets a broad range of pharmaceutical products, primarily in the areas of dermatology, eye health, cardio-metabolic, neurology, and branded generics. More information about Valeant Canada can be found at www.valeantcanada.com.

SOURCE Valeant Canada

For further information: Sébastien Beauchamp, Valeant Canada LP, Tel.: 514-744-6792, Email: sebastien.beauchamp@valeant.com